<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336396">
  <stage>Registered</stage>
  <submitdate>10/01/2011</submitdate>
  <approvaldate>14/01/2011</approvaldate>
  <actrnumber>ACTRN12611000050954</actrnumber>
  <trial_identification>
    <studytitle>Comparison of hemodynamic parameters of isoflurane and sevoflurane during lowflow controlled anesthesia</studytitle>
    <scientifictitle>Comparison of hemodynamic parameters between low flow Isoflurane and low flow Sevoflurane anesthesia during controlled ventilation with Laryngeal Mask Airway</scientifictitle>
    <utrn>U1111-1118-9670</utrn>
    <trialacronym />
    <secondaryid>There is no secondary ID</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemodynamic Parameters during anesthesia(systolic and diastolic blood pressure and Heart rate)</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>maintenance of low flow Anestheia with volume controlled ventilation through Laryngeal Mask Airway(LMA)with sevoflurane(Inhaled anesthetic) with 2-2.5% in initial phase(10 minutes) and after that maintained on 3-3.5% till we reach near the time of ending operation.,  at first we set fresh gas flow at 6 lit/min and after that the fresh gas flow decreases to 1lit/min during 10-15 minutes. hemodynamic parameters will be monitored.</interventions>
    <comparator>maintenance of low flow Anestheia with volume controlled ventilation through Laryngeal Mask Airway(LMA)with isoflurane(inhaled anesthesia) with 1.5-2% isoflurane for 10 minutes and after that 1-1.5% till we reach near the time of ending operation.at first we set fresh gas flow at 6 lit/min and after that the fresh gas flow decreases to 1lit/min during 10-15 minutes.hemodynamic parameters will be monitored.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>hemodynamic parameters which will be assessed by monitoring systolic blood pressure,diastolic blood pressure by automatic sphygmomanometer and heart rate by electrocardiogram</outcome>
      <timepoint>During Maintenance of anesthesia at a regular time.(each 5 minutes)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety wich will be assessed with stable hemodynamic status</outcome>
      <timepoint>Maintenance of anesthesia</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult patients(20-60) y.o with ASA physical status 1-2 who are candidated for elective surgery</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>difficult airway, history of malignant hyperthermia,alcoholism,uncomponsated diabetes mellitus, long duration of fasting,heavy smoking, renal failure and impared co2 absorbant.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/02/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>East Azerbaijan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tabriz University of Medical Sciences</primarysponsorname>
    <primarysponsoraddress>Golshahr street,Tabriz
5157663114</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Tabriz University of Medical Sciences</fundingname>
      <fundingaddress>Golshahr street,Tabriz
5157663114</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Laryngeal Mask Airway(LMA) is a good device for airway management which is used routinly in operating room nowadays.Low flow anesthesia is almost a new concept in maintenance of anesthesia which leads to better control of airway temperature and humidity with stable hemodynamic.
Previous studies showed that we can use isoflurane with controlled low flow anesthesia during operation. Sevoflurane is a new anesthetic which has some  priorities to other anesthetics. But there are some concerns about its use during contooled low flow anesthesia with LMA. 80 patients will be enrolled in this study. Patients will be randomized to two 40 patient groups. In one group anesthesia will be maintained with isoflurane and in the other group will be maintained by sevoflurane. All patients will be ventilated through LMA with low flow anesthesia. Hemodynamic Parameters will be noted during anestheia for each person.</summary>
    <trialwebsite>There is not web site for study</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of tabriz University of Medical Sciences</ethicname>
      <ethicaddress>Tabriz University,Daneshgah Ave, Tabriz
5157663114</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>12/11/2010</ethicsubmitdate>
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ata Mahmoodpoor</name>
      <address>General ICU,Shohada hospital, El-goli street, Tabriz
5157663114</address>
      <phone>00984113851117</phone>
      <fax />
      <email>amahmoodpoor@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ata Mahmoodpoor</name>
      <address>General ICU,Shohada hospital, El-goli street, Tabriz
5157663114</address>
      <phone>00984113851117</phone>
      <fax>00984113853171</fax>
      <email>amahmoodpoor@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Haniye Molsegi</name>
      <address>General ICU,Shohada hospital, El-goli street, Tabriz
5157663114</address>
      <phone>00989166654424</phone>
      <fax />
      <email>h.molseghi@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>